WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Damian Lillard's 35INTERVIEW: ‘There's exposure across Wall Street’ — Radio Free Asia49ers GM hopes to get Brandon Aiyuk contract extension done sooner rather than laterChiefs sign coach Andy Reid, GM Brett Veach, team president Mark Donovan to contract extensionsLowry, Connor propel Jets to 7California legislators prepare to vote on a crackdown on utility spendingSmuggling of used cars into North Korea rises amid postTibetans say compensation for Chinese land grab is too low — Radio Free AsiaNelly Korda puts bid for 6th straight victory on hold after withdrawing from Los Angeles tourneyBiden administration tightens rules for obtaining medical records related to abortion
2.0068s , 6605.5390625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Cultural Compass news portal